Patents by Inventor Barry Leonard Reed
Barry Leonard Reed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150094290Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.Type: ApplicationFiled: June 16, 2014Publication date: April 2, 2015Applicant: Acrux DDS Pty LtdInventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Traci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 8784878Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.Type: GrantFiled: December 11, 2012Date of Patent: July 22, 2014Assignee: Acrux DDS Pty Ltc.Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Traci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 8357393Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.Type: GrantFiled: December 7, 2004Date of Patent: January 22, 2013Assignee: Acrux DDS Pty Ltd.Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Taci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 8071075Abstract: The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug thereof and at least one penetration enhancer selected from safe ester sunscreens.Type: GrantFiled: October 5, 2007Date of Patent: December 6, 2011Assignee: Acrux DDS Pty Ltd.Inventors: Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Publication number: 20100166674Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.Type: ApplicationFiled: December 18, 2009Publication date: July 1, 2010Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Taci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 7387789Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a non-steroidal anti-inflammatory drug; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic or locally acting non-steroidal anti-inflammatory drug to an animal which comprises applying an effective amount of the non-steroidal anti-inflammatory drug in the form of the drug delivery system of the present invention.Type: GrantFiled: September 8, 2006Date of Patent: June 17, 2008Assignee: ACRUX DDS Pty. Ltd.Inventors: Kathryn Traci-Jane Klose, Margarita Vladislavova Bakalova, Timothy Matthias Morgan, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 7094422Abstract: The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an antifungal agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting antifungal agent to an animal which comprises applying an effective amount of the antifungal agent in the form of the drug delivery system of the present invention.Type: GrantFiled: August 20, 2003Date of Patent: August 22, 2006Assignee: Acrux DDS PTY Ltd.Inventors: Nora Yat Knork Chew, Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Patent number: 6998138Abstract: The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an anti-alopecia agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting anti-alopecia agent to an animal which comprises applying an effective amount of the anti-alopecia agent in the form of the drug delivery system of the present invention.Type: GrantFiled: August 8, 2003Date of Patent: February 14, 2006Assignee: Acrux DDS Pty. Ltd.Inventors: Nora Yat Knork Chew, Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Patent number: 6964777Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antianxiety agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antianxiety agent to an animal which comprises applying an effective amount of the antianxiety agent in the form of the drug delivery system of the present invention.Type: GrantFiled: May 2, 2003Date of Patent: November 15, 2005Assignee: Acrux DDS PTY LTDInventors: Kathryn Traci-Jane Klose, Ennio La Guardia, Timothy Matthias Morgan, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 6929801Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiParkinson agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiParkinson agent to an animal which comprises applying an effective amount of the antiParkinson agent in the form of the drug delivery system of the present invention.Type: GrantFiled: May 2, 2003Date of Patent: August 16, 2005Assignee: Acrux DDS PTY LTDInventors: Kathryn Traci-Jane Klose, Ngan Thi Kim Tran, Timothy Matthias Morgon, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 6923983Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid.Type: GrantFiled: May 2, 2003Date of Patent: August 2, 2005Assignee: Acrux DDS PTY LTDInventors: Timothy Matthias Morgan, Margarita Vladislavova Bakalova, Karthryn Traci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 6916487Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiemetic; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiemetic thereof to an animal which comprises applying an effective amount of the antiemetic in the form of the drug delivery system of the present invention.Type: GrantFiled: May 2, 2003Date of Patent: July 12, 2005Assignee: Acrux DDS PTY LTDInventors: Kathryn Traci-Jane Klose, Jianwen Zhou, Timothy Matthias Morgan, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 6916486Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an analgesic; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting analgesic to an animal which comprises applying an effective amount of the analgesic in the form of the drug delivery system of the present invention.Type: GrantFiled: May 2, 2003Date of Patent: July 12, 2005Assignee: Acrux DDS PTY LTDInventors: Kathryn Traci-Jane Klose, Felicia Maria Colagrande, Timothy Matthias Morgan, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 6818226Abstract: A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterised in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen.Type: GrantFiled: July 24, 2001Date of Patent: November 16, 2004Assignee: ACRUX DDS Pty. Ltd.Inventors: Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Publication number: 20040096405Abstract: The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an anti-alopecia agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting anti-alopecia agent to an animal which comprises applying an effective amount of the anti-alopecia agent in the form of the drug delivery system of the present invention.Type: ApplicationFiled: August 8, 2003Publication date: May 20, 2004Applicant: Monash UniversityInventors: Nora Yat Knork Chew, Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Publication number: 20040081684Abstract: The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an antifungal agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting antifungal agent to an animal which comprises applying an effective amount of the antifungal agent in the form of the drug delivery system of the present invention.Type: ApplicationFiled: August 20, 2003Publication date: April 29, 2004Applicant: Monash UniversityInventors: Nora Yat Knork Chew, Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Publication number: 20040028725Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid.Type: ApplicationFiled: May 2, 2003Publication date: February 12, 2004Applicant: Monash UniversityInventors: Timothy Matthias Morgan, Margarita Vladislavova Bakalova, Karthryn Traci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Publication number: 20040028625Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an analgesic; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting analgesic to an animal which comprises applying an effective amount of the analgesic in the form of the drug delivery system of the present invention.Type: ApplicationFiled: May 2, 2003Publication date: February 12, 2004Applicant: Monash UniversityInventors: Kathryn Traci-Jane Klose, Felicia Maria Colagrande, Timothy Matthias Morgan, Barrie Charles Finnin, Barry Leonard Reed
-
Publication number: 20040013620Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiParkinson agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiParkinson agent to an animal which comprises applying an effective amount of the antiParkinson agent in the form of the drug delivery system of the present invention.Type: ApplicationFiled: May 2, 2003Publication date: January 22, 2004Applicant: Monash UniversityInventors: Kathryn Traci-Jane Klose, Ngan Thi Kim Tran, Timothy Matthias Morgon, Barrie Charles Finnin, Barry Leonard Reed
-
Publication number: 20040013621Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiemetic; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiemetic thereof to an animal which comprises applying an effective amount of the antiemetic in the form of the drug delivery system of the present invention.Type: ApplicationFiled: May 2, 2003Publication date: January 22, 2004Applicant: Monash UniversityInventors: Kathryn Traci-Jane Klose, Jianwen Zhou, Timothy Matthias Morgan, Barrie Charles Finnin, Barry Leonard Reed